peptide backbone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Abbreviations for predicted unobserved decay: α for alpha decay, B for beta decay, 2B for double beta decay, E for electron capture, 2E for double electron capture, IT for isomeric transition, SF for spontaneous fission, * for the nuclides whose half-lives have lower bound. Predicted double beta decay has only been listed when beta decay is not also possible. (This does not apply to zirconium-96, which has been observed to decay both ways.) ^ Tantalum-180m is a "metastable isotope", meaning it is an excited nuclear isomer of tantalum-180. See isotopes of tantalum. However, the half-life of this nuclear isomer is so long that it has never been observed to decay, and it thus is an "observationally stable" primordial nuclide, a rare isotope of tantalum. This is the only nuclear isomer with a half-life so long that it has never been observed to decay. It is thus included in this list. ^^ Bismuth-209 was long believed to be stable, due to its half-life of 2.01×1019 years, which is more than a billion times the age of the universe. § Europium-151 and samarium-147 are primordial nuclides with very long half-lives of 4.62×1018 years and 1.066×1011 years, respectively.
== Life and work == Zuckerkandl was raised in Vienna, Austria in a household of intellectuals, but his family relocated in 1938 to Paris, and later Algiers, to escape the racial policy of Nazi Germany with respect to Jews. At the end of World War II, he spent one year at the University of Paris (Sorbonne), then came to the United States to study physiology—earning a master's degree in 1947 from the University of Illinois, under C. Ladd Prosser—then returned to the Sorbonne to complete a Ph.D. in biology. Zuckerkandl developed a strong interest in molecular problems; his early research at a marine biology lab in Roscoff emphasized the roles of copper oxidases and hemocyanin in the molting cycles of crabs. In 1957, Zuckerkandl met renowned chemist Linus Pauling, who was becoming interested in molecular diseases and molecular evolution as an outgrowth of his activism on topics concerning nuclear power. They arranged a post-doctoral fellowship, and Zuckerkandl (now with his wife Jane, daughter of geneticist Charles W. Metz) returned to the United States to work with Pauling at the California Institute of Technology beginning in 1959. He was an atheist.
=== Live data === Files that are actively being updated present a challenge to back up. One way to back up live data is to temporarily quiesce them (e.g., close all files), take a "snapshot", and then resume live operations. At this point the snapshot can be backed up through normal methods. A snapshot is an instantaneous function of some filesystems that presents a copy of the filesystem as if it were frozen at a specific point in time, often by a copy-on-write mechanism. Snapshotting a file while it is being changed results in a corrupted file that is unusable. This is also the case across interrelated files, as may be found in a conventional database or in applications such as Microsoft Exchange Server. The term fuzzy backup can be used to describe a backup of live data that looks like it ran correctly, but does not represent the state of the data at a single point in time. Backup options for data files that cannot be or are not quiesced include:
=== Metalloprotein–ligand interactions === The primary sequences of thousands of olfactory receptors are known from the genomes of more than a dozen organisms: they are seven-helix transmembrane proteins, but there are very few solved structures. Their sequences exhibit typical class A GPCR motifs, useful for building their structures with molecular modeling. Golebiowski, Ma and Matsunami showed that the mechanism of ligand recognition, although similar to other non-olfactory class A GPCRs, involves residues specific to olfactory receptors, notably in the sixth helix. There is a highly conserved sequence in roughly three quarters of all ORs that is a tripodal metal ion binding site, and Suslick has proposed that the ORs are in fact metalloproteins (mostly likely with zinc, copper and possibly manganese ions) that serve as a Lewis acid site for binding of many odorant molecules. Crabtree, in 1978, had previously suggested that Cu(I) is "the most likely candidate for a metallo-receptor site in olfaction" for strong-smelling volatiles which are also good metal-coordinating ligands, such as thiols. Zhuang, Matsunami and Block, in 2012, confirmed the Crabtree/Suslick proposal for the specific case of a mouse OR, MOR244-3, showing that copper is essential for detection of certain thiols and other sulfur-containing compounds. Thus, by using a chemical that binds to copper in the mouse nose, so that copper was not available to the receptors, the authors showed that the mice could not detect the thiols.
Sources: en.wikipedia.org
leukocytes with specific granules), which include the neutrophils, innate lymphoid cells, mast cells, eosinophils, and basophils. Innate lymphoid cells (ILCs) derived from common lymphoid progenitor and belong to the lymphoid lineage. Mast cells reside in connective tissues and mucous membranes and regulate the inflammatory response. They are most often associated with allergy and anaphylaxis. Basophils and eosinophils are related to neutrophils. They secrete chemical mediators that are involved in defending against parasites and play a role in allergic reactions, such as asthma. Natural killer cells (NK cells) do not directly attack invading microbes but destroy compromised host cells, such as tumor cells or virus-infected cells. NK cells recognise such cells by a condition known as "missing self", which involves low levels of a cell-surface marker called MHC I (major histocompatibility complex)—a situation that can arise in viral infection. Normal body cells are not recognized and attacked by NK cells because they express intact self MHC antigens, which inhibit NK cell activity. Monocytes, upon moving to injured tissue, turn into dendritic cells and macrophages while promoting tissue healing. The major humoral component of the innate immune response is the complement system, a biochemical cascade that attacks the surfaces of foreign cells.
=== Therapy support === In addition to therapy primarily focused on treating the tumor, the treating physician will administer supportive therapy. Furthermore, there are numerous other support services available. These can help patients and their families cope better with the diagnosis, cancer treatment, and the consequences of the disease. The following list is not a complete overview of all available support services. It consists of examples that can facilitate the initial search for suitable support for the individual patient.
=== Acting female viceregal representatives === This list includes women appointed as viceregal representatives in an acting capacity, wherein they assumed a vacated office on a temporary basis under the terms of a dormant commission.
=== Glutathione transferases === The family of glutathione transferases (GST) is extremely diverse, and therefore can be used for a number of biotechnological purposes. Plants use glutathione transferases as a means to segregate toxic metals from the rest of the cell. These glutathione transferases can be used to create biosensors to detect contaminants such as herbicides and insecticides. Glutathione transferases are also used in transgenic plants to increase resistance to both biotic and abiotic stress. Glutathione transferases are currently being explored as targets for anti-cancer medications due to their role in drug resistance. Further, glutathione transferase genes have been investigated due to their ability to prevent oxidative damage and have shown improved resistance in transgenic cultigens.
{\displaystyle {\begin{aligned}\cos \varphi &={\frac {(\mathbf {u} _{1}\times \mathbf {u} _{2})\cdot (\mathbf {u} _{2}\times \mathbf {u} _{3})}{|\mathbf {u} _{1}\times \mathbf {u} _{2}|\,|\mathbf {u} _{2}\times \mathbf {u} _{3}|}}\\\sin \varphi &={\frac {\mathbf {u} _{2}\cdot ((\mathbf {u} _{1}\times \mathbf {u} _{2})\times (\mathbf {u} _{2}\times \mathbf {u} _{3}))}{|\mathbf {u} _{2}|\,|\mathbf {u} _{1}\times \mathbf {u} _{2}|\,|\mathbf {u} _{2}\times \mathbf {u} _{3}|}},\end{aligned}}}
Sources: en.wikipedia.org
Many white Southern Christians, including church ministers, attempted to justify their support for slavery as modified by Christian paternalism. The largest denominations, the Baptist, Methodist, and Presbyterian churches, split over the slavery issue into regional organizations of the North and South.
According to the author of the study there were 137 such events in Thailand during this period. Other ASEAN nations ranked in the study were Myanmar, ranked 3; Philippines, 5; and Vietnam, 8. Climate Change Performance Index (CCPI) 2017: Of 58 nations responsible for about 90% of global energy-related CO2 emissions, Thailand was ranked 42d in taking "action on climate protection" (1=best, 61=worst), earning an assessment of "poor". Other ASEAN nations ranked were Indonesia, 22 "good"; Malaysia, 44, "poor"; and Singapore, 54, "very poor". Global Climate Risk Index 2017: Thailand ranked number 10 of 180 nations most affected by "...weather-related loss events..." during the period 1996-2015 (1=most affected, 180=least affected) according to Germanwatch. Other ASEAN nations ranked in the top 10 were Myanmar, 2; Philippines, 5; and Vietnam, 8. Climate Central: Thailand is ranked seventh (higher number=lower risk) on the "Top 20 Most At-Risk Countries" for exposure to sea level rise and coastal flooding. It estimates the number of "People living on land that will be below sea level or chronic flood levels by the end of the century, assuming current emissions trends continue, and medium sensitivity of sea level to warming." In Thailand, eight million persons, or 12% of the population, are "at-risk" according to the study. Six of ASEAN's ten member-states are on the at-risk list. Climate Change Performance Index 2016: Thailand ranked 49 of 61 (1=best, 61=worst) countries, putting it in the "Very Poor" performance category.
=== Demineralization === In the strict sense, the term demineralization should imply removing all dissolved "mineral species" from water. Thus not only removing dissolved salt as obtained by simple deionization, but also neutral dissolved "Mineral species" such as dissolved iron hydroxides (Fe(OH)3) or dissolved silica (Si(OH)4), two solutes often present in water. In this way, demineralized water has the same electrical conductivity as deionized water, but is purer because it does not contain non-ionized substances, i.e. neutral solutes. However, demineralized water is often used interchangeably with deionized water and can be also confused with softened water, depending on the exact definition used: removing only the cations susceptible to precipitate as insoluble minerals (from there, "demineralization"), or removing all the "mineral species" present in water, and thus not only dissolved ions but also neutral solute species. So, the term demineralized water is vague and deionized water or softened water should often be preferred in its place for more clarity.
Sigma is the Sigma-Aldrich's main biochemical supplier, with offerings including antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, proteins, peptides, amino acids and their derivatives.
Since bats are mammals that can fly, they are considered to be liminal beings in various traditions. In many cultures, including in Europe, bats are associated with darkness, death, witchcraft, and malevolence. Among Native Americans such as the Creek, Cherokee and Apache, the bat is identified as a trickster. An East Nigerian tale tells that the bat developed its nocturnal habits after causing the death of his partner, the bush rat, and now hides by day to avoid arrest. More positive depictions of bats exist in some cultures. In China, bats have been associated with happiness, joy and good fortune, and symbolise the "Five Blessings": longevity, riches, health, love of virtue and a peaceful passing away. The bat is sacred in Tonga and is considered the property of the king. Mayan people associated bats with the gateway to the realm of the gods since they live in caves. In the Zapotec civilisation, the bat god presided over corn and fertility.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.